Kiyatec has developed an advanced 3D cell culture technology designed to predict patient response to therapies before the treatment begins. The company’s technology utilizes patients’ own living tumor cells to create phenotypic 3D cell-based models for drug response profiling and analyzing cell-material interactions, enabling medical practitioners to isolate effective treatments for cancer patients.
Boston, MA